Search results
19 wrz 2024 · Read the new ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors. The updated management guidelines aim to: Allow for a more complete and precise estimation of risk; Provide more appropriate intervention for high-risk individuals ; Recommend less intervention for low-risk individuals
- Online Terms and Conditions
American Society for Colposcopy and Cervical Pathology...
- Guidelines
Screening Guidelines. Screening recommendations for the...
- Online Terms and Conditions
The new guidelines provide risk thresholds for clinical action (Table 1) and establish risk estimates for the development of cervical intraepithelial neoplasia grade 3 (CIN 3), adenocarcinoma in situ, or cancer (ie, CIN 3+) for different combinations of test results.
Links and resources related to cervical screening, management, and colposcopy guidelines and recommendations. USPSTF Screening Guidelines. ASCCP endorses the United States Preventative Services Task Force (USPSTF) cervical cancer screening guidelines. View Guidelines.
Screening Guidelines. Screening recommendations for the identification of precursors and prevention of cervical cancer. View Screening Guidelines. Management Guidelines & the Enduring Guidelines Process. Risk-based Management Guidelines for the abnormal screening results, including post-colposcopy or post-treatment scenarios.
The adoption of the USPSTF guidelines expands the recommended options for cervical cancer screening in average-risk individuals aged 30 years and older to include screening every 5 years with primary high-risk human papillomavirus (hrHPV) testing.
GUIDING PRINCIPLES. METHODS. SUB-SECTION. D.1 Process and Timeline. D.2 Choice of CIN3+ as Main Clinical Endpoint for Risk Estimates. D.3 Multiple Data Sets Used to Validate Risks. D.4 Estimation of Risks. D.5 Assigning Combinations of Test Results to Clinical Actions. D.6 Rating the Recommendations.
Screen-and-treat approaches: 1. Visual inspection with acetic acid (VIA) as the primary screening test, followed by treatment. 2. HPV DNA (self- or clinician-collected) as the primary screening test, followed by treatment. Screen, triage and treat approaches: 3. Cytology as the primary screening test, followed by colposcopy triage, followed by ...
